Thera-SAbDab

FARICIMAB

>   Structural Summary
TherapeuticFaricimab
Target 1VEGFA
Heavy Chain 1EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS
Light Chain 1DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK
100% seqID Fv 1 Structure1cz8 [Fvs: HL, YX]
99% seqID Fv 1 StructureNone
95-98% seqID Fv 1 Structure1bj1 [Fvs: HL, KJ], 6bft [Fvs: AB, HL]
Target 2ANGPT2
Heavy Chain 2QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSPNPYYYDSSGYYYPGAFDIWGQGTMVTVSS
Light Chain 2SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVL
100% seqID Fv 2 StructureNone
99% seqID Fv 2 StructureNone
95-98% seqID Fv 2 Structure4imk [Fvs: AD, BC], 4iml [Fvs: AB, HL]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Faricimab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 97.83%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 101 102 103 104 105 106 107 108 109 110 111 112 113
faricimab_Fv1 E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y D F T H Y G M N W V R Q A P G K G L E W V G W I N T Y T G E P T Y A A D F K R R F T F S L D T S K S T A Y L Q M N S L R A E D T A V Y Y C A K Y P Y Y Y G T S H W Y F D V W G Q G T L V T V S S
1bj1 E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y T F T N Y G M N W V R Q A P G K G L E W V G W I N T Y T G E P T Y A A D F K R R F T F S L D T S K S T A Y L Q M N S L R A E D T A V Y Y C A K Y P H Y Y G S S H W Y F D V W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
faricimab_Fv1 D I Q L T Q S P S S L S A S V G D R V T I T C S A S Q D I S N Y L N W Y Q Q K P G K A P K V L I Y F T S S L H S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y S T V P W T F G Q G T K V E I K
1bj1 D I Q M T Q S P S S L S A S V G D R V T I T C S A S Q D I S N Y L N W Y Q Q K P G K A P K V L I Y F T S S L H S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y S T V P W T F G Q G T K V E I K
Sequence identity: 97.47%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 100G 100H 100I 100J 100K 100L 101 102 103 104 105 106 107 108 109 110 111 112 113
faricimab_Fv2 Q V Q L V Q S G A E V K K P G A S V K V S C K A S G Y T F T G Y Y M H W V R Q A P G Q G L E W M G W I N P N S G G T N Y A Q K F Q G R V T M T R D T S I S T A Y M E L S R L R S D D T A V Y Y C A R S P N P Y Y Y D S S G Y Y Y P G A F D I W G Q G T M V T V S S
4iml Q V Q L V Q S G A E V K K P G A S V K V S C K A S G Y T F T G Y Y M H W V R Q A P G Q G L E W M G W I N P N S G G T N Y A Q K F Q G R V T M T R D T S I S T A Y M E L S R L R S D D T A V Y Y C A R S P N P Y Y Y D S S G Y Y Y P G A F D I W G Q G T M V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 95A 95B 96 97 98 99 100 101 102 103 104 105 106 107
faricimab_Fv2 S Y V L T Q P P S V S V A P G Q T A R I T C G G N N I G S K S V H W Y Q Q K P G Q A P V L V V Y D D S D R P S G I P E R F S G S N S G N T A T L T I S R V E A G D E A D Y Y C Q V W D S S S D H W V F G G G T K L T V L
4iml Q P G L T Q P P S V S V A P G Q T A R I T C G G N N I G S K S V H W Y Q Q K P G Q A P V L V V Y D D S D R P S G I P E R F S G S N S G N T A T L T I S R V E A G D E A D Y Y C Q V W D S S S D H Y V F G T G T K V T V L
Sequence identity: 97.47%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 100G 100H 100I 100J 100K 100L 101 102 103 104 105 106 107 108 109 110 111 112 113
faricimab_Fv2 Q V Q L V Q S G A E V K K P G A S V K V S C K A S G Y T F T G Y Y M H W V R Q A P G Q G L E W M G W I N P N S G G T N Y A Q K F Q G R V T M T R D T S I S T A Y M E L S R L R S D D T A V Y Y C A R S P N P Y Y Y D S S G Y Y Y P G A F D I W G Q G T M V T V S S
4imk Q V Q L V Q S G A E V K K P G A S V K V S C K A S G Y T F T G Y Y M H W V R Q A P G Q G L E W M G W I N P N S G G T N Y A Q K F Q G R V T M T R D T S I S T A Y M E L S R L R S D D T A V Y Y C A R S P N P Y Y Y D S S G Y Y Y P G A F D I W G Q G T M V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 95A 95B 96 97 98 99 100 101 102 103 104 105 106 107
faricimab_Fv2 S Y V L T Q P P S V S V A P G Q T A R I T C G G N N I G S K S V H W Y Q Q K P G Q A P V L V V Y D D S D R P S G I P E R F S G S N S G N T A T L T I S R V E A G D E A D Y Y C Q V W D S S S D H W V F G G G T K L T V L
4imk Q P G L T Q P P S V S V A P G Q T A R I T C G G N N I G S K S V H W Y Q Q K P G Q A P V L V V Y D D S D R P S G I P E R F S G S N S G N T A T L T I S R V E A G D E A D Y Y C Q V W D S S S D H Y V F G T G T K V T V L
Sequence identity: 96.96%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 101 102 103 104 105 106 107 108 109 110 111 112 113
faricimab_Fv1 E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y D F T H Y G M N W V R Q A P G K G L E W V G W I N T Y T G E P T Y A A D F K R R F T F S L D T S K S T A Y L Q M N S L R A E D T A V Y Y C A K Y P Y Y Y G T S H W Y F D V W G Q G T L V T V S S
6bft E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y D F D N Y G M N W V R Q A P G K G L E W V G W I N T Y T G E P T Y A A D F K R R F T F S L D T S K S T A Y L Q M N S L R A E D T A V Y Y C A K Y P H Y Y G S S H W Y F D V W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
faricimab_Fv1 D I Q L T Q S P S S L S A S V G D R V T I T C S A S Q D I S N Y L N W Y Q Q K P G K A P K V L I Y F T S S L H S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y S T V P W T F G Q G T K V E I K
6bft D I Q M T Q S P S S L S A S V G D R V T I T C S A S Q D I S N Y L N W Y Q Q K P G K A P K V L I Y F T D D L H S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y S T V P W T F G Q G T K V E I K
>   Metadata
FormatBispecific mAb
IsotypeG1;G1
Highest Clinical Trial (Aug '23)Preregistration
Estimated Status (Aug '23)Active
Recorded Developmental TechnologyDual-Affinity Re-Targeting Technology
INN Year Proposed2017
INN Year Recommended2018
Companies InvolvedChugai Pharmaceutical, Roche
Conditions Approvedna
Conditions ActiveDiabetic macular oedema, Wet age-related macular degeneration, Retinal oedema
Conditions Discontinuedna
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy